Skip to content or main menu

Erase MS

Scientific Advisory Board

Henry F. McFarland, M.D.

Dr. McFarland attended undergraduate school at the University of Arizona and medical school at the University of Colorado. He then completed a medical internship and neurology residency at Thomas Jefferson University. Following residency, Dr. McFarland did a fellowship in neurovirology at Johns Hopkins University School of Medicine and a fellowship in Immunology at the Laboratory of Tumor Biology, University College, London. Following his fellowships, Dr. McFarland returned to the faculty of the Department of Neurology, Johns Hopkins School of Medicine. In 1975, Dr. McFarland moved to NIH to join the newly formed Neuroimmunology Branch as the Deputy Chief of the Branch. In 1994, Dr. McFarland became Chief of the Neuroimmunology Branch where he remained until 2009 when he retired and became Scientist Emeritus. Dr. McFarland’s research interests have included studies of the genetic influence in multiple sclerosis (MS), studies of immune mechanisms in MS and most recently, use of MRI to study the natural history of MS. Dr. McFarland served as Clinical Director, NINDS, from 2001–2007.

Dr. McFarland has published over 250 papers dealing with the cause and treatment of multiple sclerosis. Dr. McFarland is also a co-editor of one of the standard texts on MS. He was elected a member of the American Neurological Association in 1991. Dr. McFarland has received the Dystal Award for outstanding research in multiple sclerosis in 1998 awarded jointly by the American Academy of Neurology and the National Multiple Sclerosis Society (NMSS). He was selected as the Soriano Lecturer at the American Neurological Association in 1996. In 2003, Dr. McFarland was awarded the Charcot Award for lifetime achievement in research in MS by the Multiple Sclerosis International Federation. He has served on numerous advisory committees for the National Multiple Sclerosis Society (NMSS) and is currently on the Board of Directors for the NMSS, as well as for the National Capital Chapter of the NMSS. At NIH, he served as Chair of the Medical Executive Committee as well as the Advisory Board for Clinical Research that is advisory to the Director, NIH in shaping the future direction of clinical research at NIH.

Luanne M Metz, MD, FRCPC, Calgary MS Clinic Director
Professor, Department of Clinical Neurosciences

Dr Luanne Metz is a Professor in the Department of Clinical Neurosciences at the University of Calgary. She is Calgary Multiple Sclerosis Clinic Director and Co-Leader of MS Program of the Hotchkiss Brain Program.

Dr Metz completed her MD at the University of Calgary in 1983 and after studying Internal Medicine at the University of Toronto she completed her Neurology Residency (1988) and a Fellowship in MS/Neuroimmunology in Calgary (1989).

Dr Metz is most known for her development of the Calgary MS Clinic and her development of a bench-to-bedside translational research program (in collaboration with basic scientist Dr V Wee Yong). Specific areas of research interest include clinical trial design, development of novel therapies including minocycline, study of oral corticosteroids and vitamin D, and (in collaboration with Dr SB Patten) mental health issues in MS. Dr Metz has also been working towards the development of an electronic health record to support patient care and outcomes research.

Dr Metz is widely published and holds several grants. She has been awarded the Faculty of Medicine Watanabe Distinguished Achievement Award (1999), a YWCA Woman of Distinction Award (2001), was chosen as one of the Top 40 University of Calgary Alumni in celebration of the University of Calgary 40th Anniversary (2006),, and a Division of Neurology Outstanding Achievement Award (2008) She is currently Principal Investigator of a multicentre Phase III clinical trial funded by the MS Society of Canada to determine if minocycline reduces the proportion of people with a clinically isolated syndrome suggestive of MS who develop definite MS within 2 years, and co-PI of phase IIa trials of minocycline and prolactin in optic neuritis. She is also leading development of a provincial MS registry funded by the Government of Alberta.

Daniel S. Reich, M.D., Ph.D., Chief, Translational Neuroradiology Unit, National Institute of Neurological Disorders and Stroke, National Institute of Health

After studying math and physics at Yale (1993), Dr. Reich earned a Ph.D. in visual neurophysiology at The Rockefeller University (2000) and an M.D. from Cornell University (2002). He subsequently completed residencies in neurology and diagnostic radiology and a clinical fellowship in neuroradiology at the Johns Hopkins Hospital. He is currently board-certified in both neurology and diagnostic radiology. He performed postdoctoral research under the simultaneous supervision of Peter Calabresi and Susumu Mori at Johns Hopkins, during which he applied MRI, particularly diffusion-weighted imaging, to study multiple sclerosis. The focus of the Translational Neuroradiology Unit is to develop new MRI methods to investigate the origin of disability in multiple sclerosis and related disorders and to apply those methods to patient care and to clinical trials of new drugs.

Find us on Facebook. Follow us on Twitter. YouTube. Pinterest. Subscribe to our RSS feed.

Copyright | Site By Urban Jungle | Powered by Inflight